Brief: Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities
09/01/2023 13:12
Jan 9 (Reuters) - Prime Medicine Inc PRME.O :
* PRIME MEDICINE INC -
* PRIME MEDICINE ANNOUNCES RECENT PROGRESS AND HIGHLIGHTS
2023
STRATEGIC PRIORITIES
* PRIME MEDICINE INC - STRONG CORPORATE POSITION, WITH
ROBUST
INTELLECTUAL PROPERTY POSITION AND CASH TO FUND OPERATIONS INTO
2025
* PRIME MEDICINE INC - MULTIPLE CATALYSTS EXPECTED IN 2023,
INCLUDING FIRST DEVELOPMENT CANDIDATE NOMINATION IN 1Q AND
ADDITIONAL IN VIVO DATA IN 2H
Source text for Eikon: ID:nGNX29vyHG
Further company coverage: PRME.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prime Medicine
See all newsBrief: Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm647 In Alpha-1 Antitrypsin Deficiency
Prime Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary
Prime Medicine Q2 net loss narrows on lower expenses
Brief: Prime Medicine, Inc. Q2 EPS USD -0.24
Brief: Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm577a In H1069q-Mutated Wilson Disease